Author

L. Lowes

Observed names: L Lowes, L.P. Lowes, LP Lowes, Lowes LP, Lowes, L

Observed institutions: Nationwide Children's Hospital, Abigail Wexner Research Institute

OpenAlex ID: A5089759783

AVXS-101 phase 1 gene therapy clinical trial in SMA Type 1: end-of-Study event free survival and achievement of developmental milestones

2017 · J. Mendell, S. Al-Zaidy, et al. · Neuromuscular Disorders · 11

North Star Assessment for dysferlinopathy: Longitudinal performance in the clinical outcome study of dysferlinopathy

2017 · M. James, A. Mayhew, et al. · Neuromuscular Disorders · 4

S11 Long-term follow-up of the phase 1 START trial of onasemnogene abeparvovec gene therapy in spinal muscular atrophy type 1

2021 · JR Mendell, R Shell, et al. · Thorax · 3

SMA – THERAPY

2020 · J. Mendell, R. Shell, et al. · Neuromuscular Disorders · 3

Clinical Trial Highlights

2019 · L. Rodino-Klapac, E. Pozsgai, et al. · Neuromuscular Disorders · 3

P.066 AVXS-101 gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the phase 1 clinical trial

2019 · JR Mendell, KJ Lehman, et al. · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 2

PDF

Eteplirsen, a Phosphorodiamidate Morpholino Oligomer (PMO) for Duchenne Muscular Dystrophy (DMD): Longitudinal Comparison to External Controls on Six-Minute Walk Test (6MWT) and Loss of Ambulation (LOA) (S42.004)

2017 · JR Mendell, N Goemans, et al. · Neurology · 2

322P Rasch evaluation of North Star Ambulatory Assessment and North Star Assessment for limb-girdle type muscular dystrophies in Becker muscular dystrophy

2024 · L. Lowes, M. James, et al. · Neuromuscular Disorders · 1

PCR160 Suitability of Patient-Reported Outcomes Measure Information System (PROMIS) Parent Proxy (PP) Mobility Questionnaire in Typically Developing Children Aged 3-4 Years

2023 · I. Filipovic Audhya, S. Patel, et al. · Value in Health · 1

PDF

P.351Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the onasemnogene abeparvovec phase 1/2a clinical trial

2019 · J. Mendell, R. Shell, et al. · Neuromuscular Disorders · 1

Respiratory function in eteplirsen-treated Duchenne muscular dystrophy (DMD) patients compared to natural history

2016 · B. Kinane, O. Mayer, et al. · Neuromuscular Disorders · 1

Moderate Walking Distances and Velocity Correlate with Function Comparable to 6 Minute Walk Test (S49.005)

2012 · L. Lowes, L. Alfano, et al. · Neurology · 1

Clinical Trial Readiness in Limb Girdle Muscular Dystrophy R1 (LGMDR1): A GRASP Consortium Study

2025 · Hunn SM, Alfano LN, et al. · Newcastle University ePrints (Newcastle Univesity)

PDF

215P Evaluating the responsiveness of patient reported outcome measures (PROs) to change in valosin-containing protein multisystem proteinopathy (MSP1) over 24 months

2024 · M. Iammarino, N. Reash, et al. · Neuromuscular Disorders

321P A new world: proposed model for physical therapist evaluation and management following implementation of newborn screening for Duchenne muscular dystrophy

2024 · M. Smith, M. Iammarino, et al. · Neuromuscular Disorders

387P Quantifying function from birth through adulthood in Duchenne muscular dystrophy: a cross-sectional evaluation of the Neuromuscular Gross Motor Outcome

2024 · M. Iammarino, N. Reash, et al. · Neuromuscular Disorders

Prospective observational study of FKRP-related limb-girdle muscular dystrophy R9: A GRASP consortium study

2024 · Alfano LN, James MK, et al. · Newcastle University ePrints (Newcastle Univesity)

PDF

FP.08 Evaluating the expression of spontaneous movements in infants with neuromuscular conditions using Prechtl's General Movements Assessment

2022 · M. Iammarino, L. Pietruszewski, et al. · Neuromuscular Disorders

P.64 Validity of remote evaluation of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy

2022 · L. Lowes, M. Iammarino, et al. · Neuromuscular Disorders

Covid-19 and Neuromuscular Diseases

2021 · M. James, L. Alfano, et al. · Neuromuscular Disorders

PDF

Clinical Trial Highlights

2021 · J. Mendell, P. Shieh, et al. · Neuromuscular Disorders

DMD - TREATMENT

2021 · J. Mendell, Z. Sahenk, et al. · Neuromuscular Disorders

Dmd – Biomarkers & Outcome Measures

2020 · M. Contesse, A. Sapp, et al. · Neuromuscular Disorders

Outcome Measures

2020 · M. Iammarino, N. Miller, et al. · Neuromuscular Disorders

Outcome Measures

2020 · B. Powers, L. Alcock, et al. · Neuromuscular Disorders

Works count: 38

Citation count: 33

H-index: 3

I10-index: 1